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matched unrelated donor (MMUD) transplant followed by a trans-
plant from a haplo-identical parent. Twelve patients received
MRD transplants, whereas 18 patients received alternative donor
transplants—11 MUD, 3 haplo-identical, and 4 MMUD. The
median age at transplant was 9 years (range 1.5 to 18.4 yrs). For
MRD transplants, the conditioning regimen most often utilized
cyclophosphamide 50 mg/kg  4 days and ATG 30 mg/kg  3
days. For alternative donor transplants, the conditioning regimen
most often utilized cyclophosphamide 50 mg/kg  4 days, Cam-
path 3-10 mg  4 days (dependent upon patient weight) or ATG
30 mg/kg  3 days, and TBI (single fraction 200 cGy for MUD;
two fractions 200 cGy for MMUD). Nine alternative donor recip-
ients received ATG in their preparative regimens, whereas 11
received Campath. GVHD prophylaxis was either FK506 or cy-
closporine  mini-methotrexate. The overall survival for MRD
patients was 91.7% versus 80% for alternative donor patients at a
median follow-up of 47 months (range 3 to 100 months). Of our 32
patients, there were 5 deaths: pulmonary failure with extensive,
chronic GVHD (n 1); poor graft function with infection (n 1);
and infection (n  3). For patients receiving alternative donor
transplants, the overall survival for the Campath group was 81.8%
vs. 77.8% in the ATG group. None of the Campath patients
developed extensive, chronic GVHD compared to 3/9 ATG pa-
tients. In conclusion, alternative donor transplantation using Cam-
path or ATG in the preparatory regimens offers a curative therapy
for pediatric SAA patients with survival similar to that of patients
receiving matched sibling transplants. Although follow-up is
shorter, Campath may be associated with a reduced incidence of
extensive, chronic GVHD and further investigation is warranted.
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Objective: HLA-mismatched related donor blood and marrow
transplantation (BMT) is a suitable alternative approach in patients
who lack a matched donor. We hypothesized that differences in
BMT-outcome might be inﬂuenced by age, type of leukemia and
feto-maternal tolerance. Patients: Here is the report on outcomes
after mismatched related donor BMT for leukemia in patients aged
3-53 years, performed by a single team and transplanted from April
2002 to May 2005 and followed through June 2005. 65 (31%) had
CML, 57 (28%) AML, 73 (35%) ALL and 12 (6%) MDS. 46% had
early stage disease, 30% intermediate and 24% had advanced
disease at BMT. 32(16%) of grafts were mismatched at a single
HLA locus, 93 (45%) at 2 HLA loci and 82 (40%) at 3 HLA loci.
All patients received a uniform protocol (BuCy2  ATG) for
BMT. Results: All of patients achieved full engraftment. Rates of
acute and chronic GVHD were similar in children and adults, P 
.67 and P  .20, respectively. The two-year probabilities of TRM
were 19% and 22%, and those of relapse were 25% and 17% in
children and adults, respectively. Two-year probabilities of LFS
and overall survival (OS) were 55% and 62% in children, and 61%
and 65% in adults, respectively. The two-year OS in patients who
received graft from their mother, father, sibling and offspring were
61%, 66%, 76%, and 62% (P  .40), respectively. Disease status
was a signiﬁcant impact factor on the survival. Two years OS in
early, intermediate, and advanced stage at transplantation was
77%, 60% and 45% (P  .002), respectively. Multivariate analyses
resulted that in children with advanced leukemia and BMT with
female donor were associated with higher risks of relapse, treat-
ment failure and overall mortality. However, in adult recipients,
BMT with a cousin or father donor was associated with higher
treatment failure and overall mortality and ALL was associated
with higher relapse rates. Higher CD3 dose reduced the TRM.
Conclusion: Mismatched related BMT appears to be a feasible
option in patients who lack a matched donor. The avoidance of
female donors for children and use of sibling or maternal donor for
adults is likely to present a better survival after BMT. Graft-versus-
leukemia effect might play a role in the lower relapse rates seen in
patients with AML/CML rather than lymphoid malignancies.
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Recent studies have shown nearly equivalent survival outcomes
for unrelated donor (URD) SCT in CML compared to sibling
donors. This study compared outcomes for a set of URD trans-
plants for AML and a strictly selected matching set of sibling donor
transplants. 105 adult histocompatible URD transplant recipients
with AML aged between 16 and 59 years at transplant were se-
lected from the ABMTRR database. 105 adult ﬁrst 6/6 HLA-
identical sibling transplants were selected, matched with the sub-
jects for disease stage, sex and age as a control group. There was no
signiﬁcant difference between subjects and controls in the distri-
butions of time from diagnosis to transplant, donor-recipient sex
match, prior therapies, donor age or performance status. The
transplants were carried out from 1992 to 2002 inclusive. The
median follow up of live subjects was 4.4 years and for live controls
was 6.3 years. There were 18 good risk (CR1) and 87 poor risk
(	CR1) recipients in both URD and sibling groups. Five-year
disease free survival (DFS) was not signiﬁcantly different for good-
risk URD and sibling donor recipients (62% vs 40%, P  .20), or
poor-risk URD and sibling recipients (21% vs 25%, P  .20). In a
multivariate Cox regression model, the independent risk factors for
DFS were disease stage beyond CR1 (P .001), age	49 (P .03)
and recipient CMV positivity (P  .007). Both neutrophil and
platelet engraftment were signiﬁcantly more rapid in the sibling
group but transplant related mortality at 100 days was not signif-
icantly different. There was no difference in the cumulative inci-
dence of acute GVHD grade II or above at 100 days. The cumu-
lative incidence of chronic GVHD at 1 year post transplant was
greater in good risk URD transplants compared to controls (84%
vs 61%; P .04) but not poor risk transplants. Relapse occurred in
28% of good risk URD subjects and 16% of siblings (P  .30)
while in poor risk subjects this was 39% and 29% (P  .20). Adult
URD allograft recipients for good and poor risk AML in this study
had equivalent DFS probability to sibling recipients. This study
provides a rationale for a larger prospective study of risk factors in
allogeneic transplantation for AML. The ABMTRR is an impor-
tant national data resource providing a large and readily accessible
sample frame for retrospective studies.
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Background: Donor bone marrow transplantation (BMT) may
promote chimerism in solid organ and composite tissue allografts.
This study was designed to evaluate the rationale of immunother-
apy with adoptive transfer of donor-speciﬁc cells originated from
two different MHC mismatched donors and transplanted to the
same recipients. Methods: Seven primary trimera were created
across the MHC barrier from LBN (RT1n) (n  7) and ACI
(RT1a) (n  7) donors to LEW (RT1l) recipients (n  7), under a
7-day protocol of 
-TCRmAb/CsA therapy. Bilateral intraosse-
ous BMT (70 106) was performed from LBN and ACI donors to
left and right femur respectively. Fourteen secondary trimeras
were created via adoptive transfer of MACS-sorted primary chi-
meric cells: double positive RT1n/RT1a cells (9.0  106 to 24.0 
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